Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Anti-Infective Agents

Dexamethasone

Melphalan

Lenalidomide

Dexamethasone acetate

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

HIV Protease Inhibitors

Protease Inhibitors

Enzyme Inhibitors

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)

A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years

Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)

Lenalidomide, Dexamethasone

Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years

Lenalidomide, Dexamethasone, PBSCT

Christian Straka

In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m² augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before transplantation and lenalidomide maintenance after transplantation.

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma

To compare the efficacy of both treatment regimens with regard to progression-free survival.

To assess the safety and overall survival of both treatment regimens.

To investigate other efficacy parameters of both treatment regimens

ClinAssess GmbH

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma	NCT01090089	Multiple Myelom...	Lenalidomide, D... Lenalidomide, D...	60 Years - 75 Years	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma	NCT01090089	Multiple Myelom...	Lenalidomide, D... Lenalidomide, D...	60 Years - 75 Years	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Spots Global Cancer Trial Database for lenalidomide, dexamethasone, pbsct